Advertisement

Topics

ImmunoGen Company Profile

11:16 EDT 22nd June 2018 | BioPortfolio

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates arecalled tumor-activated prodrugs ("TAPs") and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, TAPs are intended to deliver potent chemotherapy specifically to a tumor. Each TAP immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody. The small-molecule drugs are highly potent cell-killing (cytotoxic) agents, while the monoclonal antibodies identify and bind to tumor cells. An important characteristic of TAPs is that they remain inactive and nontoxic until they bind to the surface of a tumor cell, after which their full cytotoxicity is restored.

Location

128 Sidney Street
Cambridge
MA
02139
United States of America

Contact

Phone: (617) 995-2500
Fax: 617-995-2510


News Articles [55 Associated News Articles listed on BioPortfolio]

ImmunoGen: Der Gewinn hat sich auf 30% erhöht - und es sieht gut aus!

Am 24.01. hatten wir im RuMaS Express-Service auf ImmunoGen aufmerksam gemacht. Der Beitrag hatte den Titel: "ImmunoGen: Wenn der Widerstand fällt kann es nur bergauf gehen!" Am 04.02. konnten wir .....

Jobs Affected as ImmunoGen Winds Down Ops at Massachusetts Facility

ImmunoGen gave a pipeline progress report and 2017 operating results last week.

ImmunoGen closing MA plant: 20 jobs to go, $20m in savings

ImmunoGen says it is shifting drug conjugate manufacturing and quality testing to an outsourcing model and will close its Norwood facility.

FDA fast-tracks ImmunoGen’s treatment for ovarian cancer

US Food and Drug Administration (FDA) has awarded Fast Track designation to ImmunoGen’s lead programme mirvetuximab soravtansine for patients with...Read More... The post FDA fast-tracks ImmunoGen...

FDA fast-tracks ImmunoGen's treatment-resistant ovarian cancer therapy

The FDA awarded fast-track status to ImmunoGen's mirvetuximab soravtansine, being developed to treat patients with medium to  -More- 

ImmunoGen, Inc. Strategy, SWOT and Corporate Finance Report [Report Updated: 05012018] Prices from USD $175

ImmunoGen, Inc. Strategy, SWOT and Corporate Finance ReportSummaryImmunoGen, Inc. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report c...

#news #biotech Sanofi culls ImmunoGen cancer drug from clinical pipeline

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sanofi culls ImmunoGen cancer drug from clinical pipeline .Sanofi has dropped...

ImmunoGen Announces Webcast of Presentation at Deutsche Bank’s 43rd Annual Health Care Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will presen...

Drugs and Medications [0 Results]

None

PubMed Articles [28 Associated PubMed Articles listed on BioPortfolio]

HIV Env on Lockdown.

No immunogen has been found that elicits a broadly neutralizing antibody (bNAb) response sufficient for development into an HIV vaccine. In this issue of Cell Host and Microbe, Zhang et al. (2018) ra...

Differential Response of B Cells to an Immunogen, a Mitogen and a Chemical Carcinogen in a Mouse Model System

Background: B cells are specific antibody generating cells which respond to foreign intruders in the circulation. The purpose of this study was to compare the relative immunogenic potentials of three ...

Strategies for a multi-stage neutralizing antibody-based HIV vaccine.

A critical property of a prophylactic HIV vaccine is likely to be its ability to elicit broadly neutralizing antibodies (bnAbs). BnAbs typically have multiple unusual features and are generated in a f...

Sub-yearling Siberian sturgeon (Acipenser baerii) fed diet supplemented with Immunogen: Effect on growth performance, body composition, haematological and serum biochemical parameters.

In this research, the effect of Immunogen(IMNO) was investigated on growth indices, hematological parameters, and carcass composition of Siberian sturgeon (Acipenser baerii). After acclimation, fish (...

Synthetic Three-Component HIV-1 V3 Glycopeptide Immunogens Induce Glycan-Dependent Antibody Responses.

Eliciting broadly neutralizing antibody (bNAb) responses against HIV-1 is a major goal for a prophylactic HIV-1 vaccine. One approach is to design immunogens based on known broadly neutralizing epitop...

Clinical Trials [26 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer

This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for gastric cancer.

Safety and Efficacy of G17DT Immunogen in the Treatment of Advanced Pancreatic Carcinoma

This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for pancreatic cancer.

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymp

To determine the effect of HIV-1 immunogen (Remune) on AIDS-free survival, defined as the time prior to development of an AIDS-defining condition or death.

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

To evaluate safety and immunogenicity of 2 different HIV-1 peptide candidate vaccines, the UBI HIV-1 MN PND peptide immunogen and the UBI microparticulate monovalent HIV-1 MN branched pept...

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, With or Without a Candidate Vaccine

The purpose of this study is to determine the role of HIV-specific CD4 T cell responses and immune responses dependent upon these CD4 responses that develop when antiretroviral drugs are s...

Companies [7 Associated Companies listed on BioPortfolio]

ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agent...

ImmunoGen

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates arecalled tumor-activated prodrugs ("TAPs") and are based on its proprietary immunocon...

Industrial Research Limited - UK

IRL Biopharm is a highly skilled contract manufacturing business focused on developing and manufacturing novel secondary metabolites for our growing number of biotech and pharma clients around the glo...

Immunitor Corporation Co., Ltd

Immunitor Corporation Co., Ltd., is the first private biotech company formed in Thailand Technology developed by Immunitor allows to formulate any desired immunogen or antigen as an or...

Vical Incorporated

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applica...

More Information about "ImmunoGen" on BioPortfolio

We have published hundreds of ImmunoGen news stories on BioPortfolio along with dozens of ImmunoGen Clinical Trials and PubMed Articles about ImmunoGen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ImmunoGen Companies in our database. You can also find out about relevant ImmunoGen Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record